These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22432949)

  • 1. Antidepressants and the relief of osteoarthritic pain - findings from a study examining adjunctive duloxetine.
    Citrome L; Weiss-Citrome A
    Int J Clin Pract; 2012 May; 66(5):431-3. PubMed ID: 22432949
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
    Cowen PJ; Ogilvie AD; Gama J
    Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine-induced syndrome of inappropriate antidiuretic hormone secretion and seizures.
    Maramattom BV
    Neurology; 2006 Mar; 66(5):773-4. PubMed ID: 16534127
    [No Abstract]   [Full Text] [Related]  

  • 4. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duloxetine 60 mg/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study.
    Kelin K; Berk M; Spann M; Sagman D; Raskin J; Walker D; Perahia D
    Int J Clin Pract; 2010 May; 64(6):719-26. PubMed ID: 20345508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of microscopic colitis secondary to duloxetine.
    Bahin FF; Chu G; Rhodes G
    J Clin Gastroenterol; 2013 Jan; 47(1):89-90. PubMed ID: 23090036
    [No Abstract]   [Full Text] [Related]  

  • 9. [Focus on treatment success of depressed patients. Early and significant pain reduction improves chances for remission].
    MMW Fortschr Med; 2010 Mar; 152(9):78-9. PubMed ID: 20384105
    [No Abstract]   [Full Text] [Related]  

  • 10. Duloxetine in the treatment of major psychiatric and neuropathic disorders.
    Müller N; Schennach R; Riedel M; Möller HJ
    Expert Rev Neurother; 2008 Apr; 8(4):527-36. PubMed ID: 18416656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duloxetine-related galactorrhea and restless legs syndrome: a case report.
    Belli H; Akbudak M; Ural C
    Psychiatr Danub; 2013 Sep; 25(3):266-7. PubMed ID: 24048395
    [No Abstract]   [Full Text] [Related]  

  • 12. Is duloxetine effective treatment for depression with atypical features?
    Stewart JW; Deliyannides DA; McGrath PJ
    Int Clin Psychopharmacol; 2008 Nov; 23(6):333-6. PubMed ID: 18854721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression.
    Perahia DG; Quail D; Gandhi P; Walker DJ; Peveler RC
    J Affect Disord; 2008 May; 108(1-2):33-41. PubMed ID: 17905442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine use in painful conditions.
    Marcus DA
    Expert Opin Pharmacother; 2011 Jun; 12(8):1333-1340. PubMed ID: 21548724
    [No Abstract]   [Full Text] [Related]  

  • 15. Serotonin syndrome in a patient with chronic pain polypharmacy.
    Lamberg JJ; Gordin VN
    Pain Med; 2014 Aug; 15(8):1429-31. PubMed ID: 22925399
    [No Abstract]   [Full Text] [Related]  

  • 16. Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis.
    Gore M; Sadosky A; Leslie D; Tai KS; Seleznick M
    Clin Ther; 2011 Dec; 33(12):1914-31. PubMed ID: 22088416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
    Fava M; Detke MJ; Balestrieri M; Wang F; Raskin J; Perahia D
    J Psychiatr Res; 2006 Jun; 40(4):328-36. PubMed ID: 16678205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular electrophysiological effects of chronic fluoxetine and duloxetine administration on serotonergic responses in the aging hippocampus.
    Smith JE; Lakoski JM
    Synapse; 1998 Nov; 30(3):318-28. PubMed ID: 9776135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does duloxetine safely and effectively reduce the severity of diabetic peripheral neuropathic pain?
    Russell JW
    Nat Clin Pract Neurol; 2006 Jan; 2(1):18-9. PubMed ID: 16932514
    [No Abstract]   [Full Text] [Related]  

  • 20. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
    Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.